{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:22:32Z","timestamp":1773235352678,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.bbr.2014.02.024","type":"journal-article","created":{"date-parts":[[2014,2,22]],"date-time":"2014-02-22T22:02:26Z","timestamp":1393106546000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects"],"prefix":"10.1016","volume":"265","author":[{"given":"Adriana de Toledo","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-9184","authenticated-orcid":false,"given":"Karen Silvia de Carvalho","family":"Homem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Suchecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Tufik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-5676","authenticated-orcid":false,"given":"Lanfranco Ranieri Paolo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 14","key":"10.1016\/j.bbr.2014.02.024_bib0005","first-page":"11","article-title":"Monoamine dysfunction and the pathophysiology and treatment of depression","volume":"59","author":"Charney","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 6","key":"10.1016\/j.bbr.2014.02.024_bib0010","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bbr.2014.02.024_bib0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.pharmthera.2010.12.002","article-title":"Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters","volume":"129","author":"Haenisch","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bbr.2014.02.024_bib0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1073858410361780","article-title":"Corticotropin-releasing hormone, glutamate, and gamma-aminobutyric acid in depression","volume":"17","author":"Gao","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.bbr.2014.02.024_bib0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1358\/dot.2007.43.10.1122223","article-title":"Psychopathology of depression","volume":"43","author":"Leonard","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.bbr.2014.02.024_bib0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tips.2008.05.004","article-title":"Serotonin and depression: pathophysiological mechanism or marketing myth","volume":"29","author":"Cowen","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.mp.4001949","article-title":"Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies","volume":"12","author":"Ruhe","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bbr.2014.02.024_bib0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.157.1.231","article-title":"Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice","volume":"157","author":"Berman","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.brainresrev.2007.04.005","article-title":"The stress system in depression and neurodegeneration: focus on the human hypothalamus","volume":"57","author":"Bao","year":"2008","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.bbr.2014.02.024_bib0050","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.tips.2003.09.011","article-title":"Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders","volume":"24","author":"Holmes","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0055","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1046\/j.0953-816x.2001.01733.x","article-title":"Stressor categorization: acute physical and psychological stressors elicit distinctive recruitment patterns in the amygdala and in medullary noradrenergic cell groups","volume":"14","author":"Dayas","year":"2001","journal-title":"Eur J Neurosci"},{"issue":"Suppl. 1","key":"10.1016\/j.bbr.2014.02.024_bib0060","first-page":"S11-7","article-title":"Stressor-specific activation of the hypothalamic-pituitary-adrenocortical axis","volume":"49","author":"Pacak","year":"2000","journal-title":"Physiol Res"},{"key":"10.1016\/j.bbr.2014.02.024_bib0065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1210\/edrv.22.4.0436","article-title":"Stressor specificity of central neuroendocrine responses: implications for stress-related disorders","volume":"22","author":"Pacak","year":"2001","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bbr.2014.02.024_bib0070","first-page":"R1247-R55","article-title":"Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity","volume":"275","author":"Pacak","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000097587","article-title":"Suppression of adrenocorticotrophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models","volume":"84","author":"Ramos","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bbr.2014.02.024_bib0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioral despair in rats \u2013 new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hup.187","article-title":"Are CRF receptor antagonists potential antidepressants","volume":"16","author":"O\u2018Brien","year":"2001","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1527-3458.2003.tb00244.x","article-title":"The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review","volume":"9","author":"Seymour","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.bbr.2014.02.024_bib0095","first-page":"53","article-title":"An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders","volume":"11","author":"Serradeil-Le Gal","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.bbr.2014.02.024_bib0100","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/sj.mp.4001464","article-title":"Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression","volume":"9","author":"Alonso","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bbr.2014.02.024_bib0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/jpet.301.1.333","volume":"301","author":"Griebel","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.02.024_bib0110","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","article-title":"Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders","volume":"99","author":"Griebel","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbr.2014.02.024_bib0115","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2174\/1381612053764797","article-title":"Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders","volume":"11","author":"Griebel","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bbr.2014.02.024_bib0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-3565(25)33434-8","article-title":"Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs","volume":"224","author":"O\u2019Donnell","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.02.024_bib0125","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/sj.npp.1301036","article-title":"Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat","volume":"31","author":"Louis","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.02.024_bib0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.06.032","article-title":"The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats","volume":"543","author":"Shimazaki","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0024-3205(82)90394-0","article-title":"Peptides in the cerebrospinal fluid of neuropsychiatric patients: an approach to central nervous system peptide function","volume":"31","author":"Post","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0006-3223(95)00229-A","article-title":"Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls","volume":"38","author":"Pitts","year":"1995","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.02.024_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.0.1600001","article-title":"The role of corticotropin-releasing factor in depression and anxiety disorders","volume":"160","author":"Arborelius","year":"1999","journal-title":"J Endocrinol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0150","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1523\/JNEUROSCI.06-10-02908.1986","article-title":"Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress","volume":"6","author":"Chappell","year":"1986","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0155","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/(SICI)1096-9861(19960115)364:3<523::AID-CNE10>3.0.CO;2-Q","article-title":"Corticotropin-releasing factor-containing axon terminals synapse onto catecholamine dendrites and may presynaptically modulate other afferents in the rostral pole of the nucleus locus coeruleus in the rat brain","volume":"364","author":"Van Bockstaele","year":"1996","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0091-3057(86)90257-1","article-title":"REM sleep deprivation induces a decrease in norepinephrine-stimulated 3H-cyclic AMP accumulation in slices from rat brain","volume":"25","author":"Troncone","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bbr.2014.02.024_bib0165","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1523\/JNEUROSCI.10-01-00176.1990","article-title":"Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus","volume":"10","author":"Butler","year":"1990","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0170","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0361-9230(94)90170-8","article-title":"Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor","volume":"35","author":"Weiss","year":"1994","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.bbr.2014.02.024_bib0175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1749-6632.1995.tb44673.x","article-title":"The role of CRF in behavioral aspects of stress","volume":"771","author":"Heinrichs","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0180","first-page":"277","article-title":"The role of corticotropin-releasing factor in behavioural responses to stress","volume":"172","author":"Koob","year":"1993","journal-title":"Ciba Found Symp"},{"key":"10.1016\/j.bbr.2014.02.024_bib0185","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1073\/pnas.97.11.6079","article-title":"Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates","volume":"97","author":"Habib","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbr.2014.02.024_bib0190","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0022-3565(24)38220-5","article-title":"Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001","volume":"289","author":"Okuyama","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.02.024_bib0195","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0893-133X(02)00299-3","article-title":"Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist","volume":"27","author":"Heinrichs","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.02.024_bib0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s002130050645","article-title":"Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone","volume":"138","author":"Griebel","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.02.024_bib0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0167-0115(00)00196-8","article-title":"Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation","volume":"96","author":"Aguilera","year":"2000","journal-title":"Regul Pept"},{"key":"10.1016\/j.bbr.2014.02.024_bib0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cne.902610206","article-title":"Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus","volume":"261","author":"Caffe","year":"1987","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0215","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1073\/pnas.92.15.6783","article-title":"Extrapituitary expression of the rat V1b vasopressin receptor gene","volume":"92","author":"Lolait","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbr.2014.02.024_bib0220","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/35053579","article-title":"The neurobiology of attachment","volume":"2","author":"Insel","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0225","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archpsyc.58.7.655","article-title":"Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression","volume":"58","author":"Zhou","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bbr.2014.02.024_bib0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.npp.1300040","article-title":"Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model","volume":"28","author":"Keck","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.02.024_bib0235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/edrv-17-2-187","article-title":"Antidepressants and hypothalamic-pituitary-adrenocortical regulation","volume":"17","author":"Holsboer","year":"1996","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bbr.2014.02.024_bib0240","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1210\/jcem.84.6.5723","article-title":"Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity","volume":"84","author":"Dinan","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bbr.2014.02.024_bib0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/jpet.301.1.333","volume":"301","author":"Griebel","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.02.024_bib0250","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.301.1.322","volume":"301","author":"Gully","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.02.024_bib0255","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pbb.2003.12.023","article-title":"Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters","volume":"77","author":"Farrokhi","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bbr.2014.02.024_bib0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2004.06.035","article-title":"Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression","volume":"497","author":"Overstreet","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0265","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1124\/jpet.300.3.1122","article-title":"Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist","volume":"300","author":"Serradeil-Le Gal","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.02.024_bib0270","doi-asserted-by":"crossref","first-page":"R938","DOI":"10.1152\/ajpregu.00062.2007","article-title":"Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand","volume":"293","author":"Serradeil-Le Gal","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.bbr.2014.02.024_bib0275","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1196\/annals.1410.037","article-title":"Vasopressin does not mediate hypersensitivity of the hypothalamic pituitary adrenal axis during chronic stress","volume":"1148","author":"Chen","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0280","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1126\/science.1202107","article-title":"Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1","volume":"333","author":"Refojo","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbr.2014.02.024_bib0285","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/BF01291881","article-title":"Hypothalamic mechanisms mediating glutamate effects on the hypothalamo-pituitary-adrenocortical axis","volume":"104","author":"Feldman","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.bbr.2014.02.024_bib0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1196\/annals.1296.004","article-title":"Role of GABA and glutamate circuitry in hypothalamo-pituitary-adrenocortical stress integration","volume":"1018","author":"Herman","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbr.2014.02.024_bib0295","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.neuron.2008.01.022","article-title":"Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system","volume":"57","author":"Lammel","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2014.02.024_bib0300","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nature08028","article-title":"Two types of dopamine neuron distinctly convey positive and negative motivational signals","volume":"459","author":"Matsumoto","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2014.02.024_bib0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2012.01.010","article-title":"Quantification of extracellular levels of corticosterone in the basolateral amygdaloid complex of freely-moving rats: a dialysis study of circadian variation and stress-induced modulation","volume":"1452","author":"Bouchez","year":"2012","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2014.02.024_bib0310","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.neubiorev.2012.09.001","article-title":"Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation","volume":"37","author":"Haller","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bbr.2014.02.024_bib0315","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrd3702","article-title":"Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning","volume":"11","author":"Griebel","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bbr.2014.02.024_bib0320","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T22:30:07Z","timestamp":1746138607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432814000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":64,"alternative-id":["S0166432814000990"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2014.02.024","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2014.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}